Fiona E. Yull

Dedicated to advancing knowledge in the field of cancer research, Dr. Fiona E. Yull serves as an Associate Professor of Pharmacology at Vanderbilt University. Her work is centered on unraveling the complexities of NF-kappaB signaling pathways and their implications in both normal physiological processes and pathological conditions, particularly focusing on ovarian, breast, and lung cancers. Dr. Yull employs sophisticated transgenic and knockout mouse models to delve into the intricacies of how NF-kappaB signaling influences tumor initiation and progression. Her research is pivotal in developing innovative treatment strategies that could potentially transform cancer therapy. By understanding the molecular underpinnings of these signaling pathways, Dr. Yull aims to contribute to the development of more effective and targeted cancer treatments. Her recent research endeavors have been supported by significant grants, allowing her to explore cutting-edge therapeutic approaches. One of her notable projects involves modulating NF-kappaB signaling within macrophages to enhance ovarian cancer immunotherapy. This work is groundbreaking in its potential to harness the body's immune system to combat cancer more effectively. Additionally, Dr. Yull is investigating the synergistic effects of combining BET inhibitors (BETi) and PARP inhibitors (PARPi) to reduce ovarian tumor burden. This research holds promise for improving treatment outcomes for patients with ovarian cancer by targeting multiple pathways simultaneously. Through her dedication and innovative research, Dr. Yull continues to make substantial contributions to the field of cancer pharmacology. Her work not only advances scientific understanding but also holds the potential to significantly impact clinical practices and improve patient outcomes in the fight against cancer.